参考文献
[1]Shukla VV,Shah RC.Vaccinations in Primary Care[J].Indian J Pediatr,2018,85(12):1118-1127.DOI:10.1007/s12098-017-2555-2.
[2]Vetter V,Denizer G,Friedland LR,et al.Understanding modern-day vaccines:what you need to know[J].Ann Med,2018,50(2):110-120.DOI:10.1080/07853890.2017.1407035.
[3]Van Herck S,Feng B,Tang L.Delivery of STING agonists for adjuvanting subunit vaccines[J].Adv Drug Deliv Rev,2021,179:114020.DOI:10.1016/j.addr.2021.114020.
[4]Mohsen MO,Bachmann MF.Virus-like particle vaccinology,from bench to bedside[J].Cell Mol Immunol,2022,19(9):993-1011.DOI:10.1038/s41423-022-00897-8.
[5]Nooraei S,Bahrulolum H,Hoseini ZS,et al.Virus-like particles:preparation,immunogenicity and their roles as nanovaccines and drug nanocarriers[J].J Nanobiotechnology,2021,19(1):59.DOI:10.1186/s12951-021-00806-7.
[6]Zhang L,Xu W,Ma X,et al.Virus-like Particles as Antiviral Vaccine:Mechanism,Design,and Application[J].Biotechnol Bioprocess Eng,2023,28(1):1-16.DOI:10.1007/s12257-022-0107-8.
[7]Kheirvari M,Liu H,Tumban E.Virus-like Particle Vaccines and Platforms for Vaccine Development[J].Viruses,2023,15(5):1109.DOI:10.3390/v15051109.
[8]McFall-Boegeman H,Huang X.Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines[J].Expert Rev Vaccines,2022,21(4):453-469.DOI:10.1080/14760584.2022.2029415.
[9]Mohsen MO,Zha L,Cabral-Miranda G,et al.Major findings and recent advances in virus-like particle(VLP)-based vaccines[J].Semin Immunol,2017,34:123-132.DOI:10.1016/j.smim.2017.08.014.
[10]Al-Barwani F,Donaldson B,Pelham SJ,et al.Antigen delivery by virus-like particles for immunotherapeutic vaccination[J].Ther Deliv,2014,5(11):1223-1240.DOI:10.4155/tde.14.74.
[11]Liu J,Dai S,Wang M,et al.Virus like particle-based vaccines against emerging infectious disease viruses[J].Virol Sin,2016,31(4):279-287.DOI:10.1007/s12250-016-3756-y.
[12]Win SJ,Ward VK,Dunbar PR,et al.Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway[J].Immunol Cell Biol,2011,89(6):681-688.DOI:10.1038/icb.2010.161.
[13]Donaldson B,Lateef Z,Walker GF,et al.Virus-like particle vaccines:immunology and formulation for clinical translation[J].Expert Rev Vaccines,2018,17(9):833-849.DOI:10.1080/14760584.2018.1516552.
[14]Zepeda-Cervantes J,Ramírez-Jarquín JO,Vaca L.Interaction Between Virus-Like Particles(VLPs)and Pattern Recognition Receptors(PRRs)From Dendritic Cells(DCs):Toward Better Engineering of VLPs[J].Front Immunol,2020,11:1100.DOI:10.3389/fimmu.2020.01100.
[15]Mohsen MO,Gomes AC,Vogel M,et al.Interaction of Viral Capsid-Derived Virus-Like Particles(VLPs)with the Innate Immune System[J].Vaccines(Basel),2018,6(3):37.DOI:10.3390/vaccines6030037.
[16]Roy P,Noad R.Virus-like particles as a vaccine delivery system:myths and facts[J].Adv Exp Med Biol,2009,655:145-158.DOI:10.1007/978-1-4419-1132-2_11.
[17]Ungaro F,Conte C,Quaglia F,et al.VLPs and particle strategies for cancer vaccines[J].Expert Rev Vaccines,2013,12(10):1173-1193.DOI:10.1586/14760584.2013.836909.
[18]Han JC,Li QX,Fang JB,et al.GII.P16-GII.2 Recombinant Norovirus VLPs Polarize Macrophages Into the M1 Phenotype for Th1 Immune Responses[J].Front Immunol,2021,12:781718.DOI:10.3389/fimmu.2021.781718.
[19]Jeong H,Seong BL.Exploiting virus-like particles as innovative vaccines against emerging viral infections[J].J Microbiol,2017,55(3):220-230.DOI:10.1007/s12275-017-7058-3.
[20]Huang X,Wang X,Zhang J,et al.Escherichia coli-derived virus-like particles in vaccine development[J].NPJ Vaccines,2017,2:3.DOI:10.1038/s41541-017-0006-8.
[21]Naskalska A,PyrćK.Virus Like Particles as Immunogens and Universal Nanocarriers[J].Pol J Microbiol,2015,64(1):3-13.
[22]Fuenmayor J,Gòdia F,Cervera L.Production of virus-like particles for vaccines[J].N Biotechnol,2017,39(Pt B):174-180.DOI:10.1016/j.nbt.2017.07.010.
[23]Vogl T,Hartner FS,Glieder A.New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris[J].Curr Opin Biotechnol,2013,24(6):1094-1101.DOI:10.1016/j.copbio.2013.02.024.
[24]Gupta R,Arora K,Roy SS,et al.Platforms,advances,and technical challenges in virus-like particles-based vaccines[J].Front Immunol,2023,14:1123805.DOI:10.3389/fimmu.2023.1123805.
[25]Liu W,Jiang H,Zhou J,et al.Recombinant dengue virus-like particles from Pichia pastoris:efficient production and immunological properties[J].Virus Genes,2010,40(1):53-59.DOI:10.1007/s11262-009-0418-2.
[26]Saraswat S,Athmaram TN,Parida M,et al.Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles(CHIK-VLPs)and Its Evaluation as a Potential Vaccine Candidate[J].PLoS Negl Trop Dis,2016,10(7):e0004782.DOI:10.1371/journal.pntd.0004782.
[27]Wurm FM.Production of recombinant protein therapeutics in cultivated mammalian cells[J].Nat Biotechnol,2004,22(11):1393-1398.DOI:10.1038/nbt1026.
[28]Zhu J.Mammalian cell protein expression for biopharmaceutical production[J].Biotechnol Adv,2012,30(5):1158-1170.DOI:10.1016/j.biotechadv.2011.08.022.
[29]Li C,Liu F,Liang M,et al.Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL/6 mice[J].Vaccine,2010,28(26):4294-4300.DOI:10.1016/j.vaccine.2010.04.025.
[30]Fontana D,Kratje R,Etcheverrigaray M,et al.Immunogenic virus-like particles continuously expressed in mammalian cells as a veterinary rabies vaccine candidate[J].Vaccine,2015,33(35):4238-4246.DOI:10.1016/j.vaccine.2015.03.088.
[31]Schwarz H,Zhang Y,Zhan C,et al.Small-scale bioreactor supports high density HEK293 cell perfusion culture for the production of recombinant Erythropoietin[J].J Biotechnol,2020,309:44-52.DOI:10.1016/j.jbiotec.2019.12.017.
[32]Kim C,Kim JD,Seo SU.Nanoparticle and virus-like particle vaccine approaches against SARS-CoV-2[J].J Microbiol,2022,60(3):335-346.DOI:10.1007/s12275-022-1608-z.
[33]Felberbaum RS.The baculovirus expression vector system:A commercial manufacturing platform for viral vaccines and gene therapy vectors[J].Biotechnol J,2015,10(5):702-714.DOI:10.1002/biot.201400438.
[34]Daniell H,Rai V,Xiao Y.Cold chain and virus-free oral polio booster vaccine made in lettuce chloroplasts confers protection against all three poliovirus serotypes[J].Plant Biotechnol J,2019,17(7):1357-1368.DOI:10.1111/pbi.13060.
[35]Nakahira Y,Mizuno K,Yamashita H,et al.Mass Production of Virus-Like Particles Using Chloroplast Genetic Engineering for Highly Immunogenic Oral Vaccine Against Fish Disease[J].Front Plant Sci,2021,12:717952.DOI:10.3389/fpls.2021.717952.
[36]Shirbaghaee Z,Bolhassani A.Different applications of virus-like particles in biology and medicine:Vaccination and delivery systems[J].Biopolymers,2016,105(3):113-132.DOI:10.1002/bip.22759.
[37]Harrison BD,Wilson TM.Milestones in the research on tobacco mosaic virus[J].Philos Trans R Soc Lond B Biol Sci,1999,354(1383):521-529.DOI:10.1098/rstb.1999.0403.
[38]Rasor BJ,Vögeli B,Landwehr GM,et al.Toward sustainable,cell-free biomanufacturing[J].Curr Opin Biotechnol,2021,69:136-144.DOI:10.1016/j.copbio.2020.12.012.
[39]Hu VT,Kamat NP.Cell-free protein synthesis systems for vaccine design and production[J].Curr Opin Biotechnol,2023,79:102888.DOI:10.1016/j.copbio.2022.102888.
[40]Tinafar A,Jaenes K,Pardee K.Synthetic Biology Goes Cell-Free[J].BMC Biol,2019,17(1):64.DOI:10.1186/s12915-019-0685-x.
[41]Taheri T,Seyed N,Mizbani A,et al.Leishmania-based expression systems[J].Appl Microbiol Biotechnol,2016,100(17):7377-7385.DOI:10.1007/s00253-016-7712-4.
[42]Pattyn J,Hendrickx G,Vorsters A,et al.Hepatitis B Vaccines[J].J Infect Dis,2021,224(12Suppl 2):S343-S351.DOI:10.1093/infdis/jiaa668.
[43]Zuckerman JN,Zuckerman AJ,Symington I,et al.Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines[J].Hepatology,2001,34(4Pt 1):798-802.DOI:10.1053/jhep.2001.27564.
[44]Cai X,Zheng W,Pan S,et al.A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice[J].Antiviral Res,2018,149:48-57.DOI:10.1016/j.antiviral.2017.11.007.
[45]Mobini S,Chizari M,Mafakher L,et al.Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus[J].Front Immunol,2020,11:2074.DOI:10.3389/fimmu.2020.02074.
[46]Joe C,Chatterjee S,Lovrecz G,et al.Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity[J].Vaccine,2020,38(22):3892-3901.DOI:10.1016/j.vaccine.2020.03.007.
[47]Whitacre DC,Peters CJ,Sureau C,et al.Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance[J].Hum Vaccin Immunother,2020,16(2):251-268.DOI:10.1080/21645515.2019.1689745.
[48]Huang J,Liao Q,Ooi MH,et al.Epidemiology of Recurrent Hand,Foot and Mouth Disease,China,2008-2015[J].Emerg Infect Dis,2018,24(3):432-442.DOI:10.3201/eid2403.171303.
[49]Zhu P,Ji W,Li D,et al.Current status of hand-foot-and-mouth disease[J].J Biomed Sci,2023,30(1):15.DOI:10.1186/s12929-023-00908-4.
[50]Wang Z,Zhou C,Gao F,et al.Preclinical evaluation of recombinant HFMD vaccine based on enterovirus 71(EV71)virus-like particles(VLP):Immunogenicity,efficacy and toxicology[J].Vaccine,2021,39(31):4296-4305.DOI:10.1016/j.vaccine.2021.06.031.
[51]Cao L,Mao F,Pang Z,et al.Protective effect of enterovirus-71(EV71)virus-like particle vaccine against lethal EV71 infection in a neonatal mouse model[J].Mol Med Rep,2015,12(2):2473-2480.DOI:10.3892/mmr.2015.3680.
[52]Zhao H,Li HY,Han JF,et al.Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice[J].Sci Rep,2015,5:7878.DOI:10.1038/srep07878.
[53]Kim HJ,Son HS,Lee SW,et al.Efficient expression of enterovirus 71 based on virus-like particles vaccine[J].PLoS One,2019,14(3):e0210477.DOI:10.1371/journal.pone.0210477.
[54]Krug PW,Wang L,Shi W,et al.EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination[J].Sci Adv,2023,9(20):eadg6076.DOI:10.1126/sciadv.adg6076.
[55]Xu Y,Ma S,Huang Y,et al.Virus-like particle vaccines for poliovirus types 1,2,and 3 with enhanced thermostability expressed in insect cells[J].Vaccine,2019,37(17):2340-2347.DOI:10.1016/j.vaccine.2019.03.031.
[56]Bahar MW,Porta C,Fox H,et al.Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines[J].NPJ Vaccines,2021,6(1):5.DOI:10.1038/s41541-020-00267-3.
[57]Pielnaa P,Al-Saadawe M,Saro A,et al.Zika virus-spread,epidemiology,genome,transmission cycle,clinical manifestation,associated challenges,vaccine and antiviral drug development[J].Virology,2020,543:34-42.DOI:10.1016/j.virol.2020.01.015.
[58]Mittal S,Federman HG,Sievert D,et al.The Neurobiology of Modern Viral Scourges:ZIKV and COVID-19[J].Neuroscientist,2022,28(5):438-452.DOI:10.1177/10738584211009149.
[59]Liu Y,Liu J,Du S,et al.Evolutionary enhancement of Zika virus infectivity in Aedes aegypti mosquitoes[J].Nature,2017,545(7655):482-486.DOI:10.1038/nature22365.
[60]Garg H,Mehmetoglu-Gurbuz T,Joshi A.Recent Advances in Zika Virus Vaccines[J].Viruses,2018,10(11):631.DOI:10.3390/v10110631.
[61]Cimica V,Galarza JM,Rashid S,et al.Current development of Zika virus vaccines with special emphasis on virus-like particle technology[J].Expert Rev Vaccines,2021,20(11):1483-1498.DOI:10.1080/14760584.2021.1945447.
[62]Boigard H,Alimova A,Martin GR,et al.Zika virus-like particle(VLP)based vaccine[J].PLoS Negl Trop Dis,2017,11(5):e0005608.DOI:10.1371/journal.pntd.0005608.
[63]Vang L,Morello CS,Mendy J,et al.Zika virus-like particle vaccine protects AG129 mice and rhesus macaques against Zika virus[J].PLoS Negl Trop Dis,2021,15(3):e0009195.DOI:10.1371/journal.pntd.0009195.
[64]Carrera J,Aktepe TE,Earnest L,et al.Adenovirus vector produced Zika virus-like particles induce a long-lived neutralising antibody response in mice[J].Vaccine,2023,41(33):4888-4898.DOI:10.1016/j.vaccine.2023.06.068.
[65]Cimica V,Williams S,Adams-Fish D,et al.Zika Virus-Like Particle(VLP)vaccine displaying Envelope(E)protein CD loop antigen elicits protective and specific immune response in a murine model[J].Biochem Biophys Res Commun,2020,529(3):805-811.DOI:10.1016/j.bbrc.2020.05.161.
[66]Diamos AG,Pardhe MD,Sun H,et al.Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domainⅢsynergistically enhances immunogenicity[J].Vaccine,2020,38(18):3455-3463.DOI:10.1016/j.vaccine.2020.02.089.
[67]Soliman M,Oredein O,Dass CR.Update on Safety and Efficacy of HPV Vaccines:Focus on Gardasil[J].Int J Mol Cell Med,2021,10(2):101-113.DOI:10.22088/IJMCM.BUMS.10.2.101.
[68]Roden R,Stern PL.Opportunities and challenges for human papillomavirus vaccination in cancer[J].Nat Rev Cancer,2018,18(4):240-254.DOI:10.1038/nrc.2018.13.
[69]Kuter BJ,Garland SM,Giuliano AR,et al.Current and future vaccine clinical research with the licensed 2-,4-,and 9-valent VLP HPV vaccines:What′s ongoing,what′s needed?[J].Prev Med,2021,144:106321.DOI:10.1016/j.ypmed.2020.106321.
[70]Petrosky E,Bocchini JA Jr,Hariri S,et al.Use of 9-valent human papillomavirus(HPV)vaccine:updated HPV vaccination recommendations of the advisory committee on immunization practices[J].MMWR Morb Mortal Wkly Rep,2015,64(11):300-304.
[71]Dewi KS,Chairunnisa S,Swasthikawati S,et al.Production of codon-optimized Human papillomavirus type 52 L1 virus-like particles in Pichia pastoris BG10 expression system[J].Prep Biochem Biotechnol,2023,53(2):148-156.DOI:10.1080/10826068.2022.2048262.
[72]Li M,Liang Z,Chen C,et al.Virus-Like Particle-Templated Silica-Adjuvanted Nanovaccines with Enhanced Humoral and Cellular Immunity[J].ACS Nano,2022,16(7):10482-10495.DOI:10.1021/acsnano.2c01283.
[73]Zhai L,Peabody J,Pang YS,et al.A novel candidate HPV vaccine:MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9[J].Antiviral Res,2017,147:116-123.DOI:10.1016/j.antiviral.2017.09.012.
[74]Qian C,Yang Y,Xu Q,et al.Characterization of an Escherichia coli-derived triple-type chimeric vaccine against human papillomavirus types 39,68 and 70[J].NPJ Vaccines,2022,7(1):134.DOI:10.1038/s41541-022-00557-y.
[75]Zhang X,Meng D,Li H,et al.Validation of Luminex immunological and competitive Luminex immunological assays for clinical immunogenicity assessment of a 14-valent recombinant human papillomavirus vaccine[J].J Med Virol,2023,95(8):e29050.DOI:10.1002/jmv.29050.
[76]Olczak P,Matsui K,Wong M,et al.RG2-VLP:a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer[J].J Virol,2022,96(13):e0056622.DOI:10.1128/jvi.00566-22.
[77]Pushko P,Tretyakova I.Influenza Virus Like Particles(VLPs):Opportunities for H7N9 Vaccine Development[J].Viruses,2020,12(5):518.DOI:10.3390/v12050518.
[78]Quan FS,Lee YT,Kim KH,et al.Progress in developing virus-like particle influenza vaccines[J].Expert Rev Vaccines,2016,15(10):1281-1293.DOI:10.1080/14760584.2016.1175942.
[79]Smith T,O′Kennedy MM,Wandrag D,et al.Efficacy of a plant-produced virus-like particle vaccine in chickens challenged with Influenza A H6N2 virus[J].Plant Biotechnol J,2020,18(2):502-512.DOI:10.1111/pbi.13219.
[80]Li M,Guo P,Chen C,et al.Bacteriophage T4 Vaccine Platform for Next-Generation Influenza Vaccine Development[J].Front Immunol,2021,12:745625.DOI:10.3389/fimmu.2021.745625.
[81]Kim KH,Lee YT,Park S,et al.Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus[J].Virology,2019,535:179-188.DOI:10.1016/j.virol.2019.07.008.
[82]Smith GE,Flyer DC,Raghunandan R,et al.Development of influenza H7N9 virus like particle(VLP)vaccine:homologous A/Anhui/1/2013(H7N9)protection and heterologous A/chicken/Jalisco/CPA1/2012(H7N3)cross-protection in vaccinated mice challenged with H7N9 virus[J].Vaccine,2013,31(40):4305-4313.DOI:10.1016/j.vaccine.2013.07.043.
[83]Hendin HE,Lavoie PO,Gravett JM,et al.Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity[J].NPJ Vaccines,2022,7(1):42.DOI:10.1038/s41541-022-00463-3.
[84]Nerome K,Imagawa T,Sugita S,et al.The potential of a universal influenza virus-like particle vaccine expressing a chimeric cytokine[J].Life Sci Alliance,2023,6(1):e202201548.DOI:10.26508/lsa.202201548.
[85]Imagawa T,Arasaki Y,Maegawa K,et al.Advancing usability of an influenza hemagglutinin virus-like particle vaccine expressing a chimeric cytokine[J].Virol J,2023,20(1):102.DOI:10.1186/s12985-023-02076-1.
[86]Wang Z,Li Z,Shi W,et al.A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus[J].Sci Adv,2023,9(25):eabo4100.DOI:10.1126/sciadv.abo4100.
[87]Yadav T,Kumar S,Mishra G,et al.Tracking the COVID-19 vaccines:The global landscape[J].Hum Vaccin Immunother,2023,19(1):2191577.DOI:10.1080/21645515.2023.2191577.
[88]Yilmaz IC,Ipekoglu EM,Bulbul A,et al.Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection[J].Allergy,2022,77(1):258-270.DOI:10.1111/all.15091.
[89]Volkmann A,Koopman G,Mooij P,et al.A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques[J].Front Immunol,2022,13:857440.DOI:10.3389/fimmu.2022.857440.
[90]Ward BJ,Gobeil P,Séguin A,et al.Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19[J].Nat Med,2021,27(6):1071-1078.DOI:10.1038/s41591-021-01370-1.
